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Abstract: Paclitaxel is a diterpenoid isolated from Taxus brevifolia. It is effective for various 
cancers, especially ovarian and breast cancer. Due to its aqueous insolubility, it is administered 
dissolved in ethanol and Cremophor® EL (BASF, Ludwigshafen, Germany), which can cause 
serious allergic reactions. In order to eliminate Cremophor EL, paclitaxel was formulated as 
a nanosuspension by high-pressure homogenization. The nanosuspension was lyophilized 
to obtain the dry paclitaxel nanoparticles (average size, 214.4 ± 15.03 nm), which enhanced 
both the physical and chemical stability of paclitaxel nanoparticles. Paclitaxel dissolution 
was also enhanced by the nanosuspension. Differential scanning calorimetry showed that the 
crystallinity of paclitaxel was preserved during the high-pressure homogenization process. 
The pharmacokinetics and tissue distribution of paclitaxel were compared after intravenous 
administration of paclitaxel nanosuspension and paclitaxel injection. In rat plasma, paclitaxel 
nanosuspension exhibited a significantly (P , 0.01) reduced area under the concentration 
curve (AUC)0–∞ (20.343 ± 9.119 µg ⋅ h ⋅ mL-1 vs 5.196 ± 1.426 µg ⋅ h ⋅ mL-1), greater clearance 
(2.050 ± 0.616 L ⋅ kg-1 ⋅ h-1 vs 0.556 ± 0.190 L ⋅ kg-1 ⋅ h-1), and shorter elimination half-life 
(5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution. In contrast, the 
paclitaxel nanosuspension resulted in a significantly greater AUC0–∞ in liver, lung, and spleen 
(all P , 0.01), but not in heart or kidney.
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Introduction
Paclitaxel, the first of the microtubule stabilizing agents, is a diterpenoid derived from 
the bark of the Pacific yew tree (Taxus brevifolia).1–3 Clinical trials have shown that 
paclitaxel has antitumoral activity, particularly against ovarian carcinoma, breast   cancer, 
and nonsmall cell lung cancer.4 Paclitaxel has been hailed by the National Cancer Insti-
tute as the most significant advance in chemotherapy of the period 1970–1990.2
In view of its aqueous insolubility, paclitaxel has to be dissolved in a mixture of 
50% ethanol and 50% Cremophor® EL (BASF, Ludwigshafen, Germany), which is 
a polyoxyethylated castor oil. Cremophor has been proved to be associated with a 
number of side effects, including hypersensitivity and neurotoxicity.5–8 The use of 
prophylactic steroids and histamine receptor antagonists as anti-allergic pre-medication 
may decrease the incidence and severity of acute hypersensitivity reactions. However, 
milder reactions have still been found to occur in 5%–30% of patients.9,10
The extensive clinical use of paclitaxel was somewhat delayed due to the lack 
of appropriate delivery vehicles. There is a need for the development of alternating 
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adverse reaction. Numerous attempts have been made to 
improve the solubility and pharmacological properties of 
paclitaxel, such as cosolvents, emulsions, micelles, lipo-
somes, microspheres nanoparticles, cyclodextrins, pastes, 
and implants.1
An alternative formulation is a nanosuspension, which is 
a colloidal dispersion of nanosized drug particles produced 
by an appropriate size-reduction method and stabilized by 
a suitable stabilizer.11–13 According to Noyes–Whitney and 
Ostwald–Freundlich principles, the particle size in the nano-
meter range can lead to an increased dissolution velocity and 
saturation solubility for a nanosuspension, which is usually 
also accompanied by an increase in bioavailability.11,14,15 
Nanosuspensions are useful dosage forms for poorly   soluble 
drugs.13,16,17 Nanosuspensions may also show passive 
  targeting similar to colloidal drug carriers after intravenous 
administration.18 Following modification to the surface 
with special stabilizers, some active targeting may also be 
achieved in vivo with nanosuspensions.13
Techniques such as high-pressure homogenization and 
wet milling are often used to produce nanosuspensions of 
small size suitable for pharmaceutical uses.17,19–21 The high-
pressure homogenization technique has been extensively 
described with regard to particle size-reduction efficiency.20 
As it is very simple, time-saving, and an organic solvent-free 
process, high-pressure homogenization presents advantages 
over other milling techniques. However, with high-pressure 
homogenization, the drug particles should be sufficiently 
small to pass through the homogenization gaps.17
In this study, high-pressure homogenization was 
evaluated for the paclitaxel nanosuspension preparation 
for intravenous administration. The paclitaxel nanosus-
pension was characterized for its particle size distribution 
and   morphology. We also selected the surfactants and 
optimized the parameters of the homogenization proce-
dure to produce a stable nanosuspension with small and 
narrow-distributed sizes. The paclitaxel crystalline state 
was   studied before and following the high-pressure homog-
enization process to assess whether the initial crystalline 
state was preserved, which was important for long-term 
stability. To assess the in vivo properties of paclitaxel 
nanosuspension, the pharmacokinetics and tissue distribu-
tion were also investigated.
Materials and methods
Materials
Raw material of paclitaxel and paclitaxel injection (taxol) 
was obtained from Nanjing Aosaikang Medical Group Co 
Ltd (Nanjing, China). Norethisterone was provided by the 
National Institute for the Control of Pharmaceutical and 
Biological Products (Beijing, China). Poloxamer 188 was 
provided by BASF (Ludwigshafen, Germany). Polyethylene 
glycol 400 (PEG-400) and sodium carboxymethyl cellulose 
(CMC-Na) were purchased from Shantou Xilong Chemical 
Plant (Guangdong, China). Tween® 80 was purchased from 
Sinopharm Chemical Reagent Co Ltd (Shanghai, China). 
Lecithin PC-90T was purchased from Shanghai Taiwei 
Medical Group Co Ltd (Shanghai, China). Tyloxapol was 
purchased from Shanghai Jingchun Chemical Reagent Co Ltd 
(Shanghai, China). Carbomer was purchased from Haidian 
Huiyou Co Ltd (Beijing, China). High-performance liquid 
chromatography (HPLC)-grade acetonitrile and methanol 
were obtained from Wanqing Chemical Reagent Co Ltd 
(Nanjing, China). All other chemicals and reagents were of 
analytical grade.
Preparation of paclitaxel nanosuspension
The paclitaxel nanosuspension was prepared by Ultra-Turrax® 
homogenization followed by high-pressure homogenization. 
Poloxamer 188 and PEG-400 were dissolved in 50 mL of 
water to obtain the aqueous surfactant solution. Paclitaxel 
powder (50 mg) was dissolved in 4 mL of mixed solution 
containing ethanol (2 mL) and acetidin (2 mL) to form the oil 
phase solution, which was poured into the aqueous surfactant 
solution, with continuous mixing. The initial suspension 
was then evaporated to remove organic solvents and was 
subjected to a pre-homogenization with an Ultra Turrax T25 
homogenizer (IKA Instruments Ltd, Staufen, Germany) at 
10,000 rpm for 10 minutes at room temperature. This coarse 
suspension was then circulated respectively for six cycles 
at 300, 500, and 800 bar pressure through the NS1001L2K 
high-pressure homogenizer (Niro Soavi S.p.A. Co, Parma, 
Italy) as a form of pre-milling. Finally, the suspension was 
homogenized for 20 cycles at 1000 bar until an equilibrium 
size was reached. The samples were withdrawn after the 
homogenization size-reduction steps for size-distribution 
analysis. The nanosuspension was lyophilized immediately 
to obtain a dry powder. The samples of nanosuspension 
were dispensed into a glass flask and frozen at -80°C and 
then transferred to a YO-230 freeze-dryer (Thermo Savant, 
Waltham, MA), and dried at -30°C for 36 hours with a 
vacuum degree of 200 Pa. The lyophilized product was 
re-dispersed with water for intravenous administration. 
Re-dispersion was by manual shaking for 1 minute and the 
re-dispersion volume being equivalent to the original volume 
of the nanosuspension.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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characterization of paclitaxel 
nanosuspension
Particle size and polydispersity index (PI) 
measurement
The mean particle size and the PI of the paclitaxel nano-
suspension under different homogenization conditions 
were determined by dynamic light scattering with a 
  Zetasizer 3000HS system (Malvern Instruments, Malvern, 
  Worcestershire, UK). Three observations were recorded for 
each sample. The diameters reported were calculated using 
volume distribution from Gaussian distribution which indi-
cated the width of a particle distribution.
Zeta potential (ZP) analysis
The ZP is a measure of the electric charge at the surface of the 
particles indicating the physical stability of colloidal systems. 
The ZP values being higher than |30 mV| indicate electrostatic 
long-term stability of aqueous dispersions.22 In this study, 
the ZP values were assessed by determining the particle 
electrophoretic mobility using ZP equipment (Brookhaven 
Instruments, Holtsville, NY). The nanosuspension samples for 
ZP values analysis were added to the small sample dispersion 
unit. Three observations were recorded for each sample.
Morphology
Morphological evaluation of paclitaxel nanoparticles was 
conducted by transmission electron microscopy. The samples 
were placed over a copper grid coated with carbon film and 
air-dried, and then were stained with 0.1% phosphotungstic 
acid. Finally, the samples were air dried and then observed 
with an H-7650 transmission electron microscope (Hitachi 
Ltd, Tokyo, Japan).
crystalline state evaluation
Crystalline state evaluation was conducted by differential 
scanning calorimetry (DSC) to indicate any transformation 
to amorphous state during the high-pressure homogenization 
process. A heating rate of 10°C per minute was employed 
over the range of 50°C–300°C. Samples were analyzed in 
standard aluminum sample pans, with an empty pan used 
as a reference. Thermograms of paclitaxel nanosuspension 
samples were recorded using a NETZSCH DSC-204 differ-
ential scanning calorimeter (Netzsch, Selb, Germany).
Dissolution study
A ZRS-8G dissolution apparatus (Tianjin Tianda Tianfa 
Technology Co Ltd, Tianjin, China) operating at a rotation 
speed of 75 rpm was used for in vitro testing of paclitaxel 
dissolution. All dissolution tests were run in triplicate on 
an equivalent of 10 mg of paclitaxel in nanosuspension. 
  Phosphate buffered saline (PBS) (pH 7.4) with 1% Tween 
80 was used as the dissolution media. The volume and 
temperature of the dissolution medium were 250 mL and 
37°C ± 0.5°C, respectively. At each predetermined sampling 
time, 1 mL of sample was withdrawn using sampling port 
attached with 0.22 µm filter disc, and 1 mL blank dissolu-
tion medium was added back into the vessels through the 
sampling port. Samples were centrifuged, and the resulting 
supernatant was diluted in a mobile phase, and 20 µL volume 
was injected into the HPLC for analysis.
stability study
Storage stability was studied by storing the lyophilized 
nanosuspension samples at 4°C and room temperature for 
3 months. Periodically, samples were removed, and the par-
ticle size, PI, and ZP were measured. In addition, paclitaxel 
stability in the nanosuspension was examined by determining 
the amount of parent drug remaining after specific storage 
periods.
Pharmacokinetics study
Male Sprague Dawley (SD) rats (six rats each group) weigh-
ing 230–270 g were obtained from the Laboratory Animal 
Center of Nanjing Medical University. The rats were accli-
matized for at least 1 week before experimentation, fed 
with standard diet, and allowed water ad libitum. All animal 
experiments were evaluated and approved by the Animal 
Ethics Committee of Nanjing University of Technology. 
Rats received intravenous injection of paclitaxel (10 mg/kg) 
or paclitaxel nanosuspension (10 mg/kg) via the tail vein. At 
predetermined time points (5, 10, 15, and 30 minutes, and 
then 1, 2, 4, 6, 8, and 12 hours), the rats were anesthetized 
with diethyl ether, and the blood was collected from the 
retro-orbital sinus into heparin (10 µL, 500 IU/mL)-treated 
tubes. The blood samples were immediately centrifuged at 
3000 rpm for 15 minutes to isolate the plasma. The collected 
plasma was stored at –80°C in an ultra-low temperature 
freezer (Thermo Fisher Scientific, Waltham, MA) for further 
analysis.
To determine the paclitaxel concentration, 50 µL anorethis-
terone (25 µg ⋅ mL-1) was added to 100 µL plasma followed by 
adding 1 mL diethyl ether. Each sample was vortexed for 
5 minutes with a XW-80A vortex mixer (Qingpu Huxi Instru-
ment Factory, Shanghai, China). After centrifugation (Centri-
fuge 5810R, Eppendorf, Hauppauge, NY) at 12,000 rpm for 
10 minutes to precipitate the proteins, the supernatant was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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removed to clean test tubes and evaporated until dry under 
a stream of nitrogen (Hengao Technology Development Co, 
Tianjin, China) at 37°C. Residues were dissolved in 100 µL 
of mobile phase, and 20 µL aliquots were injected into the 
HPLC for analysis.
Tissue distribution study
Male ICR (imprinting control region) mice (32 mice each 
group) weighing 18–27 g were obtained from the Laboratory 
Animal Center of Nanjing Medical University. The mice were 
acclimatized for at least 1 week before experimentation, fed 
with standard diet, and allowed water ad libitum. All animal 
experiments were evaluated and approved by the Animal Eth-
ics Committee of Nanjing University of   Technology. Mice 
in each group received an intravenous paclitaxel injection 
(10 mg/kg) or paclitaxel nanosuspension (10 mg/kg) via the 
tail vein. At predetermined time points (5, 15, and 30 minutes, 
and then 1, 2, 4, 8, and 12 hours), four mice from each group 
were sacrificed, and the liver, kidney, spleen, heart, lung, and 
brain were collected, washed, weighed, and homogenized in 
an Ultra Turrax T25 homogenizer (IKA Instruments Ltd) in 
1 mL of salt water. The collected tissue samples were stored 
at -80°C for further analysis.
To determine the paclitaxel concentration, 50 µL ano-
rethisterone (50 µg ⋅ mL-1) was added to 100 µL of tissue 
homogenate, followed by adding 3 mL diethyl ether. Each 
sample was vortexed for 2 minutes. After centrifugation at 
4000 rpm for 10 minutes to precipitate the proteins, 1 mL of 
the supernatant was removed to clean test tubes and evapo-
rated under a stream of nitrogen at 40°C. Residues were dis-
solved in 100 µL of mobile phase, and 20 µL aliquots were 
injected into the HPLC for analysis.
hPLc analysis
The HPLC system composed of a Shimadzu pump (LC20-
ATvp; Kyoto, Japan), an autosampler, and a wavelength 
detector was used with data acquisition by LCsolution 
Lite software (Shimadzu). The HPLC separation was 
performed on a Dikma Diamonsil C18 analytical column 
(150 mm × 4.6 mm, particle size 5 µm) (Dikma Co, 
  Beijing, China) and a C18 precolumn of the same packing 
(10 mm × 4.6 mm). The mobile phase consisted of methanol, 
acetonitrile, and water (40:34:26, v/v). It was filtered through 
a 0.45 µm nylon filter and degassed in an ultrasonic bath 
(Kunshan Ultrasonic Instruments Co Ltd, Shanghai, China) 
before use. All samples were analyzed under isocratic elution 
at a flow rate of 1 mL/min and at a wavelength of 228 nm. 
The column temperature was maintained at 30°C.
The HPLC method was validated for the determination 
of paclitaxel in biological matrix. The limit of quantification 
(LOQ) (50 ng/mL in plasma or 100 ng/mL in tissue homo-
genate), which was determined as the paclitaxel peak, was 
identifiable and reproducible. A calibration curve was prepared 
using seven calibration standards (0.1–40.0 µg/mL in plasma 
or 0.1–120.0 µg/mL in tissue homogenate). Intraday and 
interday accuracy and precision were determined by analysis 
of the 0.5, 5.0, and 20.0 µg/mL concentrations in plasma and 
0.5, 5.0, and 60.0 µg/mL concentrations in tissue homogenate. 
Arterial spin labeling (ASL) relative recoveries from plasma 
and tissues were determined by comparing the concentration 
of extracted samples (0.5, 5.0, and 20.0 µg/mL in plasma and 
0.5, 5.0, and 20.0 µg/mL in tissue homogenate) with the unex-
tracted standards containing the same amount of the analyte. 
In all the cases, three replicate samples were determined.
Pharmacokinetics and statistical analysis
Pharmacokinetic analysis was carried out using 3P97 phar-
macokinetic software (Chinese Pharmacological Associa-
tion, Beijing, China). Model discrimination was based on 
Akaike information criteria (AIC). The area under the plasma 
concentration-time profiles (AUC), the distribution half-life 
(t1/2,α), the elimination half-life (t1/2,β), the mean residence time 
(MRT), and total plasma clearance (CL) were calculated. The 
areas under the tissue distribution curves were calculated by 
the log-linear trapezoidal method. Statistical significance on 
pharmacokinetic parameter differences among the treatment 
groups were analyzed by Student’s t-test using SPSS Statis-
tics (v 11.0; IBM Corporation, Somers, NY), and statistical 
significance was defined by P , 0.05.
Results
selection of the surfactants
Surfactants were the most important factor maintaining the 
stability of paclitaxel nanosuspensions after the high-pressure 
homogenization. The surfactants were selected from the 
  general and safe surfactants such as poloxamer 188, PEG-400, 
CMC-Na, Tween 80, lecithin, tyloxapol, and carbomer.
As seen in Tables 1 and 2, the particle size of paclitaxel 
nanosuspension changed much according to different 
  surfactants. The nanosuspension prepared with lecithin 
flocculated quickly, and the results of particle size could not 
be determined. PEG-400, Tween 80, and tyloxapol were not 
eligible based on the results of particle size, and ZP values 
were lower than |30 mV|, indicating electrostatic instability. 
All paclitaxel nanosuspension prepared with one surfactant 
flocculated after 4 weeks under room temperature.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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As seen in Table 3, the combination of two surfactants 
enhanced the stability of paclitaxel nanosuspension based on 
the ZP values. The smallest particle size was obtained with 
the combination of poloxamer 188 and PEG-400, which were 
selected as the surfactants.
The influence of the proportion of poloxamer 188 and 
PEG-400 was investigated at the same experiment condition 
when the concentrations of paclitaxel and surfactant were 
fixed (0.04% and 0.08%, w/v). As shown in Figure 1, the 
proportion extent 1:1–1:2 was suitable.
The influence of the proportion of surfactants and pacli-
taxel on particle size was also investigated when concentration 
of paclitaxel was fixed (0.04%, w/v). As seen in Figure 2, an 
increased drug concentration needed a corresponding increase 
of the proportion. The optimized proportion was 1:1–3:1.
Process parameters: homogenization 
pressure and cycles
The mean particle size and PI of paclitaxel nanosuspen-
sions were determined by photon correlation spectroscopy 
to qualify the productions. The influence of homogenization 
pressure and cycles on the particle size and PI were shown 
in Figures 3 and 4. The high-pressure homogenization with 
increased cycle numbers resulted in the formation of smaller 
paclitaxel particles and PI. The particle size and PI further 
decreased during 6–20 cycles. However, experiments with 
homogenization cycles increased 25 from 20 failed to provide 
further decrease in particle size, which elucidated that the 
suspensions could not become smaller but could become 
more uniform during these cycles. To avoid blockage of 
homogenizer gap and chamber, the paclitaxel coarse powder 
was homogenized at 300, 500, and 800 bar pressure for six 
cycles respectively for pre-milling. The homogenization 
pressure was then increased to 1000 bar for 20 cycles until 
an equilibrium size was reached.
Paclitaxel nanosuspension
After the homogenization step, the nanosuspension was 
immediately lyophilized to obtain the dried paclitaxel nano-
suspension which maintained both the physical and chemical 
stability of the drug. There was no significant change in the 
paclitaxel nanosuspension size after re-dispersion of the 
lyophilized particles in glycerin–water. As seen in Figure 5, 
the form of the paclitaxel nanosuspension was regular rod-
shaped crystals.
crystalline state evaluation
Crystalline state evaluation was carried out after the high-
pressure homogenization process. As can be seen from the 
DSC thermograms (Figure 6), the peaks for raw material 
of paclitaxel and paclitaxel nanoparticles were identical, 
with two typical melting points, which indicated that the 
crystalline state was apparently unaltered following the 
homogenization operation.
Dissolution
The dissolution profiles for paclitaxel in PBS (pH 
7.4) after high-pressure homogenization are shown in 
(  Figure 7). A 91% drug dissolution was achieved after the 
high-pressure homogenization, compared with less than 5% 
of raw material.
stability of nanosuspension
The physical stability of lyophilized paclitaxel nanosuspen-
sion was evaluated over 3 months at room temperature. 
  During this storage period, the particle size did not change, 
Table 2 The influence of different surfactants on the stability of paclitaxel nanosuspension
Time Carbomer Poloxamer 188 PEG-400 Tween® 80 CMC-Na Tyloxapol
0 255.9 ± 17.7 294.9 ± 23.7 278.9 ± 20.1 334.2 ± 31.0 735.5 ± 57.3 339.9 ± 34.8
2 weeks 268.9 ± 22.6 305.7 ± 16.2 296.2 ± 34.7 375.5 ± 22.9 620.3 ± 67.9 317.2 ± 24.5
3 weeks 253.2 ± 14.6 329.9 ± 27.9 272.5 ± 12.5 338.7 ± 38.4 517.7 ± 47.6 354.7 ± 33.1
Abbreviations: cMc-Na, sodium carboxymethyl cellulose; Peg-400, polyethylene glycol 400.
Table 1 The influence of different surfactants on the particle size, PI, and zeta potential of paclitaxel nanosuspension
Parameter Carbomer Poloxamer 188 PEG-400 Tween® 80 CMC-Na Tyloxapol
Particle size, nm 255.9 ± 17.5 294.9 ± 25.9 278.9 ± 45.8 334.2 ± 21.1 735.5 ± 66.4 339.9 ± 32.4
PI 0.267 ± 0.04 0.143 ± 0.08 0.151 ± 0.08 0.204 ± 0.07 0.302 ± 0.11 0.124 ± 0.07
Zeta potential, mV -34.9 ± 5.3 -31.6 ± 8.6 -27.4 ± 8.7 -18.5 ± 8.8 -60 ± 14.6 -7.4 ± 2.1
Abbreviations: cMc-Na, sodium carboxymethyl cellulose; Peg-400, polyethylene glycol 400; PI, polydispersity index.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and paclitaxel stability was maintained with more than 99% 
of paclitaxel remaining in the nanosuspension. The phenom-
enon indicated that the lyophilized product had a shelf-life 
of at least 3 months.
Pharmacokinetics
The analytical method for paclitaxel determination in plasma 
has been established.23,24 The LOQ for the quantification of 
paclitaxel was 50 ng/mL in plasma. The linear range was 
0.1–40.0 µg/mL (R2 = 0.9992) in plasma. Intraday and inter-
day precision was 3.3% and 3.7%, respectively. Paclitaxel 
relative recoveries from the plasma were 97.7%.
The plasma concentration–time profiles of paclitaxel 
obtained are shown in Figure 8, and the correspond-
ing pharmacokinetic parameters are shown in Table 4. 
The pharmacokinetics of paclitaxel was best described 
by a two-compartment model as shown by the lower 
AIC and higher r2 values. Although both of the plasma 
profiles declined in a bi-exponential fashion, their pro-
files were markedly different with paclitaxel nano-
suspension exhibiting a very rapid distribution phase 
(t1/2,α = 0.186 ± 0.077 hours) compared with paclitaxel injec-
tion (t1/2,α = 0.495 ± 0.114 hours). In contrast, the elimination 
phase (t1/2,β) for the paclitaxel nanosuspension formulation was 
longer (t1/2,β = 5.645 ± 2.941 hours) compared with paclitaxel 
injection (t1/2,β = 3.774 ± 1.352 hours). The plasma AUC0–∞ 
for paclitaxel injection solution (20.343 ± 9.119 µg ⋅ h ⋅ mL-1) 
was approximately four-fold greater than paclitaxel nano-
suspension (5.196 ± 1.426 µg ⋅ h ⋅ mL-1), but the MRT 
(3.199 ± 3.718 hours) for the paclitaxel nanosuspension 
formulation was longer than that observed for the paclitaxel 
injection solution (2.753 ± 0.943 hours). In rat plasma, pacli-
taxel was measurable at 24 hours after injection of paclitaxel 
nanosuspension, but only up to 12 hours after intravenous 
paclitaxel injection solution. Thus, it was apparent that the 
paclitaxel nanosuspension formulation maintained lower 
plasma paclitaxel concentrations but for a longer duration 
compared with the paclitaxel injection solution.
Tissue distribution
The analytical method for paclitaxel determination in tissue 
homogenate has been established.24 The LOQ for the quan-
tification of paclitaxel was 100 ng/mL in tissue homogenate 
(heart, liver, spleen, lung, kidney, brain). The linear range was 
0.1–120.0 µg/g (R2 was 0.9921–0.9996), respectively. Intra-
day and interday precision was 3.1%–4.7% and 4.0%–5.11%, 
respectively. Paclitaxel relative recoveries from the plasma 
were 96.9%–98.4%, respectively.
In contrast to the plasma profiles, in all tissues except 
the heart and kidney, significantly higher paclitaxel con-
centrations were paclitaxel injection solution (P , 0.001) 
(Figure 9). The increase in AUC0–∞ ranged from 2.38-fold 
Table 3 The influence of combinatorial surfactants on the size, PI, and zeta potential of paclitaxel nanosuspension
Parameter Carbomer + 
tyloxapol
Carbomer +  
poloxamer 188
Carbomer +  
PEG-400
Tyloxapol +  
poloxamer 188
Poloxamer 188 + 
PEG-400
Poloxamer 188 +   
CMC-Na
Particle size, nm 314.1 ± 13.4 336.4 ± 13.5 255.7 ± 14.8 330.6 ± 21.5 210.6 ± 16.8 376.2 ± 49.5
PI   0.21 ± 0.06   0.26 ± 0.04   0.26 ± 0.05   0.12 ± 0.03   0.16 ± 0.06   0.35 ± 0.08
Zeta potential, mV -33.4 ± 4.8 -36.3 ± 5.6 -34.8 ± 6.4 -22.6 ± 4.7 -30.3 ± 5.3 -45.1 ± 11.8
Abbreviations: cMc-Na, sodium carboxymethyl cellulose; Peg-400, polyethylene glycol 400; PI polydispersity index.
190
200
210
220
230
240
250
260
1:3
P
a
r
t
i
c
l
e
 
s
i
z
e
 
(
n
m
)
Poloxamer 188:PEG-400
5:1 3:1 2:1 1:1 1:2 1:5
Figure 1 The influence of different ratios of poloxamer 188 and PEG-400 on the 
particle size.
Abbreviation: Peg-400, polyethylene glycol 400.
204
206
208
210
212
214
216
218
220
222
15:1
P
a
r
t
i
c
l
e
 
s
i
z
e
 
(
n
m
)
Surfactant:Paclitaxel
1:1 2:1 3:1 6:1 9:1 12:1
Figure 2 The influence of different ratios of surfactant and paclitaxel on the size 
of nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1503
Paclitaxel nanosuspension
200
210
220
230
240
250
260
270
280
290
6
P
a
r
t
i
c
l
e
 
s
i
z
e
s
 
(
n
m
)
Cycles
800 bar
1000 bar
1300 bar
25 20 15 12 9
Figure  3  The  influence  of  homogenization  pressure  and  cycle  number  on  the 
particle size of nanosuspension.
in the lung to 11.45-fold in the spleen, whereas the heart 
experienced a 19% reduction (Table 5).
Discussion
DSC (Figure 6) profiles of paclitaxel nanoparticles were not 
affected, indicating that the crystalline state of paclitaxel 
appeared to be unaltered following the homogenization 
operation, which is important for long-term stability. The 
two melting peaks of paclitaxel nanoparticles were slightly 
ahead of the peaks of raw material, possibly because the 
nanosuspension had smaller particle size and larger surface 
area. When the outside temperature rose, the rate of heat 
transfer from surface to the center of paclitaxel nanoparticles 
was higher than that of paclitaxel raw material, which made 
the nanosuspension more sensitive to external temperature.
The plasma pharmacokinetics of paclitaxel given in the 
nanosuspension formulation was markedly different compared 
with the paclitaxel injection solution. The in vivo   properties 
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Figure 4 The influence of homogenization pressure and cycle number on the PI of 
nanoparticles (standard deviation values are not reported).
Abbreviation: PI, polydispersity index.
of a nanosuspension formulation strongly depend on the 
nanoparticle size, dissolution rate, and nature.13   Particles that 
dissolve rapidly in the blood would be expected to exhibit 
similar pharmacokinetic behavior to a drug in solution form. 
This was observed with flurbiprofen nanosuspension, which 
has similar pharmacokinetics and tissue distribution as a flur-
biprofen solution after intravenous administration in rats.25 It 
is thought to be due to the rapid dissolution of the flurbiprofen 
nanoparticles in the bloodstream. The in vitro dissolution 
results (Figure 7) indicated that the paclitaxel nanoparticles 
might dissolve in the blood quickly, which was consistent 
with the above theory. Although the plasma AUC of pacli-
taxel nanosuspension was less than 30% of the AUC of the 
paclitaxel injection solution, the plasma profiles indicated 
that the nanosuspension formulation maintained low plasma 
drug for a longer period of time. The results were consistent 
with the study of asulacrine nanosuspension.26
The pharmacokinetic profile in rats after intravenous 
administration of paclitaxel nanosuspension dropped rapidly 
in plasma concentration to 2 µg/mL in 30 minutes. We sug-
gested that this might be due to the rapid uptake of rather 
slowly dissolving paclitaxel nanoparticles by the reticuloen-
dothelial system (RES). Previous studies have shown that 
slow dissolving nanocrystals were taken up by the phago-
cytic cells of the mononuclear phagocyte system (MPS), 
primarily the Kupper cells in the liver, spleen, and lung.26,27 
Their lipophilic character might permit passage through the 
Figure  5  Transmission  electron  microscopy  of  paclitaxel  nanosuspension. 
Magnification: 10,000×.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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phagolysosomal membrane, and as a result they can leave 
the cellular vesicle, enter the cytoplasm, and then excite the 
cell by diffusing down the drug concentration gradient.13 
This effect would result in a pharmacokinetic profile with 
significantly reduced AUC, but prolonged half-life.26
The paclitaxel nanosuspension in the phagocytic cells 
might slowly dissolve and diffuse into the blood circula-
tion to maintain blood concentrations for a longer duration. 
This could be the reason why a low paclitaxel nanosuspen-
sion concentration was observed for a prolonged time after 
it was given to the rat. Higher plasma clearance and remark-
ably increased tissue concentrations could also support 
rapid clearance of paclitaxel from the blood circulation by International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the RES. Despite the enhanced plasma clearance, a longer 
t1/2,β for paclitaxel nanosuspension was observed, likely 
due to the enhanced distribution (11-fold) of the paclitaxel 
  nanosuspension out of the bloodstream and uptake into the 
tissues such as the liver, kidney, and lung. PEG-modification 
of the surface of slowly dissolving drug crystals could reduce 
the macrophage uptake as observed with nanoparticles.28 
This would increase circulation time and allow the particles 
to leak out of discontinuities in tumor vasculature. The 
enhanced accumulation via the enhanced permeability and 
retention effect resulted in passive targeting.29 Therefore, 
the PEG-modification of paclitaxel nanosuspension would 
avoid macrophage uptake and allow for longer duration in 
the blood circulation. As a consequence, enhanced tumor 
accumulation of the nanocrystals may occur.26
Table 4 Pharmacokinetic parameters in rats after intravenous 
injection of PTX-NO and PTX-INJ (n = 6)
Parameters PTX-NO PTX-INJ
α/h-1   4.177 ± 1.537a   1.466 ± 0.366
β/h-1   0.142 ± 0.049   0.204 ± 0.082
Vc, L ⋅ kg-1   0.748 ± 0.263   0.697 ± 0.271
t1/2,α, hours 0.1863 ± 0.077a   0.495 ± 0.114
t1/2,β, hours   5.646 ± 2.941   3.774 ± 1.352
AUc0–∞, µg ⋅ h ⋅ mL-1   5.196 ± 1.426b 20.343 ± 9.119
cL(s), L ⋅ kg-1 ⋅ h-1   2.050 ± 0.616a   0.556 ± 0.190
MrT, hours   3.199 ± 3.718   2.753 ± 0.943
Notes: aP , 0.05 vs PTX-INJ; bP , 0.01 vs PTX-INJ.
Abbreviations: AUc, area under concentration curve; cL, total plasma clearance; 
MrT,  mean  residence  time;  PTX-INJ,  paclitaxel  injection;  PTX-NO,  paclitaxel 
nanosuspension; t1/2,α, distribution half-life; t1/2,β, elimination half-life.
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For paclitaxel nanosuspension, the drug nanocrystals could 
circulate in the blood as submicron particles for a certain time 
period. The nanocrystals might then be recognized as foreign 
matter and be rapidly cleared by phagocytic cells of MPS which 
are abundant in special tissues and organs such as liver, spleen, 
and lung.30 It has been shown that the uptake of nanoparticles 
by RES organs following intravenous administration might take 
anywhere from a few minutes to hours, depending on particle 
size and composition.31 Therefore, the paclitaxel nanocrystals 
in paclitaxel nanosuspension had a markedly higher concen-
tration compared with paclitaxel injection solution in these 
organs. Meanwhile the drug concentration in kidney and heart 
decreased. Similar results were reported in the literature.18,26 In 
brain homogenate, paclitaxel was measurable until 12 hours 
postinjection of paclitaxel nanosuspension, while the concen-
tration was negligible after intravenous paclitaxel injection 
solution. This phenomenon indicated nanosuspension could 
easily enter the brain through the blood–brain barrier, which is 
important for the research of brain targeted therapy.
It is contradictory to uptake the nanocarriers by the RES 
system while keeping the target character of nanocarriers. 
The uptake of nanocarriers by RES led to the high drug 
concentration in liver which indicated that the liver toxicity 
was theoretically increased. In the pre-experiments of the 
pharmacokinetic study, all female rats died after the injection 
of paclitaxel injection (15 mg/kg), and the male rats showed 
severe symptoms such as tremors and sticky plasma; while 
rats injected with paclitaxel nanosuspension (15 mg/kg) all 
survived, and there was no significant toxicity reaction. This 
phenomenon could prove that the nanosuspension has lower International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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toxicity than the   paclitaxel   injection. The actual toxicity in 
liver should be proved by long-term toxicity tests. If liver is 
the target organ of a drug, the drug has potential application 
in the clinic. In this study, the nanosuspension and injection 
were administered with equal doses in order to study the 
different pharmacokinetic characters of paclitaxel. In the 
pharmacodynamics study, the paclitaxel nanosuspension 
could be administered with much lower doses to achieve good 
therapeutic effects for liver cancer, which is one of the main 
targets of paclitaxel. In low doses, the side effects of paclitaxel 
should be ignored as the liver concentration of paclitaxel was 
much higher compared with other organs.
Conclusion
The nanosuspension formulations of paclitaxel with the 
smaller particle size could be effectively produced using 
the high-pressure homogenization method. The method 
was shown to be simple and adequate for drug particle size 
reduction and did not seem to alter the crystalline state of the 
drug, which is important for long-term stability. To overcome 
particle growth during long-term storage of nanosuspen-
sion formulations, lyophilization was carried out in order to 
assess the feasibility of nanosuspension in dry products. The 
paclitaxel nanosuspension exhibited a significantly reduced 
AUC0–∞, greater CL, shorter t1/2,β in plasma and resulted in 
a significantly greater AUC0–∞ in the liver, lung, and spleen 
compared with the paclitaxel solution.
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